Xiamen Ginposome Pharmatech

Xiamen Ginposome Pharmatech is a specialized biotechnology company based in China, focusing on the research, development, and industrialization of complex liposomal drug delivery systems. The company utilizes its proprietary Ginposome technology platform to develop high-end nanomedicines that improve the pharmacokinetic profiles and safety of potent therapeutic agents. Its primary therapeutic focus lies in oncology and infectious diseases, with a pipeline featuring liposomal formulations of doxorubicin, irinotecan, and amphotericin B. Ginposome Pharmatech operates state-of-the-art R&D centers and GMP-compliant manufacturing facilities to support the full lifecycle of drug development from formulation to commercial production. By addressing the challenges of drug solubility and targeted delivery, the company aims to provide more effective treatment options for patients with difficult-to-treat cancers and systemic infections. The firm also engages in strategic collaborations and provides CDMO services for partners seeking expertise in nanoparticle formulation.